comparemela.com

Latest Breaking News On - Randomized clinical - Page 5 : comparemela.com

Alirocumab Approved for Heterozygous Familial Hypercholesterolemia in Patients 8 Years and Older

Nearly a decade after becoming the first PCSK9 inhibitor to receive approval from the FDA, alirocumab (Praluent) has now received approval for pediatric patients with HeFH based on data from a phase 3 trial.

15 Effective Home Remedies For Constipation

Viaskin Milk Patch Returns Mixed Results in Phase 1/2 Trial

Viaskin milk patch shows promise in cow’s milk allergy, particularly in children aged 2-11 with 300 μg dose, though the other doses examined failed to prove significant benefit.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.